praliciguat has been researched along with Albuminuria* in 1 studies
1 trial(s) available for praliciguat and Albuminuria
| Article | Year |
|---|---|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Impaired nitric oxide signaling through soluble guanylate cyclase has been implicated in the pathophysiology of diabetic kidney disease. Praliciguat, a soluble guanylate cyclase stimulator that amplifies nitric oxide signaling, inhibited kidney inflammation and fibrosis in animal models.. Praliciguat treatment for 12 weeks did not significantly reduce albuminuria compared with placebo in the primary efficacy analysis. Nonetheless, the observed changes in urine albumin-creatinine ratio, BP, and metabolic variables may support further investigation of praliciguat in diabetic kidney disease.. A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy/Diabetic Kidney Disease as Measured by Albuminuria, NCT03217591. Topics: Aged; Albuminuria; Blood Pressure; Constipation; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diarrhea; Dizziness; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Guanylyl Cyclase C Agonists; Heart Rate; Humans; Male; Middle Aged; Placebos; Pyrazoles; Pyrimidines; Syncope | 2020 |